Answers are grounded in this paper and cite their sources.
SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) is a rare, aggressive malignancy with limited treatment options, and its immunobiology and predictive biomarkers remain poorly characterized. We report a 49-year-old woman with metastatic SDUS who progressed after first-line gemcitabine plus docetaxel. Tumor profiling revealed loss of MSH2 expression, microsatellite instability-high (MSI-H) status, and a tumor mutational burden (TMB) of 35.82 mutations/Mb. Following palliative radiotherapy to a symptomatic left supraclavicular nodal conglomerate, the patient initiated dostarlimab within the phase I GARNET trial and achieved a complete radiological response after six cycles. Treatment was discontinued after 12 cycles because of immune-related duodenitis and arthritis requiring immunosuppressive therapy. At the last follow-up in June 2026, no evidence of disease was detected, approximately 32 months after treatment discontinuation and total duration of complete response of 42 months. To our knowledge, this is the first reported case of SDUS harboring coexisting deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) and TMB-high features in which a durable complete radiological response was observed following dostarlimab treatment. This case highlights the potential value of comprehensive molecular profiling to identify patients who may benefit from immune checkpoint inhibition, although the predictive value of these biomarkers and the efficacy of immunotherapy in SDUS remain to be established.
No takes yet. Share an insight, caveat, or question.
Yaringaño et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: